APA (7th ed.) Citation

K, M., L, B., K, S., IGH, S., M, v. L., P, B., . . . C, H. (2026). Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients. Acta haematologica, 149(2), 155. https://doi.org/10.1159/000545792

Chicago Style (17th ed.) Citation

K, Mayer, Birk L, Schwab K, Schmidt-Wolf IGH, von Lilienfeld-Toal M, Brossart P, Glasmacher A, and Hahn-Ast C. "Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients." Acta Haematologica 149, no. 2 (2026): 155. https://doi.org/10.1159/000545792.

MLA (9th ed.) Citation

K, Mayer, et al. "Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients." Acta Haematologica, vol. 149, no. 2, 2026, p. 155, https://doi.org/10.1159/000545792.